The neuroinflammation pathway is a central mechanism in neurodegenerative diseases, involving the coordinated activation of innate immune cells in the brain in response to pathological insults. While acute neuroinflammation serves a protective role, chronic neuroinflammation contributes to neuronal dysfunction and death.
Neuroinflammation is initiated by:
- DAMPs (Damage-Associated Molecular Patterns) — ATP, HMGB1, nucleic acids released from damaged neurons
- PAMPs (Pathogen-Associated Molecular Patterns) — viral/bacterial components in rare infectious triggers
- Endogenous misfolded proteins — Aβ, tau, α-synuclein aggregates acting as danger signals
These triggers activate pattern recognition receptors (PRRs) on microglia and astrocytes, triggering a signaling cascade that produces pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species.
flowchart TD
A["DAMPs/PAMPs"] --> B["TLR4/TLR9/RAGE"]
B --> C["MyD88/TRIF Adaptors"]
C --> DNF-κB/I["RF3 Activation"]
D --> E["Pro-inflammatory Gene Transcription"]
E --> FTNF-α, IL-1β, I["L-6 Release"]
F --> G["Microglial M1 Polarization"]
F --> H["Astrocyte Reactivity"]
G --> I["ROS/RNS Production"]
G --> J["Complement Activation C1q, C3"]
I --> K["Synaptic Pruning"]
J --> K
H --> L["BBB Disruption"]
L --> M["Peripheral Immune Cell Infiltration"]
K --> N["Neuronal Dysfunction"]
N --> O["Chronic Inflammation Loop"]
O --> A
| Receptor |
Ligands |
Signaling Adapters |
Disease Relevance |
| TLR4 |
Aβ, HMGB1, LPS |
MyD88, TRIF |
AD, PD |
| TLR9 |
DNA, Aβ aggregates |
MyD88 |
AD, MS |
| RAGE |
Aβ, HMGB1, S100 |
NF-κB, MAPK |
AD, PD, ALS |
| NLRP3 |
Aβ, MSU, ATP |
ASC, caspase-1 |
AD, PD |
| Cytokine |
Source Cells |
Primary Effects |
Therapeutic Target |
| TNF-α |
Microglia, astrocytes |
Neuronal apoptosis |
Etanercept, Infliximab |
| IL-1β |
Microglia, monocytes |
Tau phosphorylation |
Anakinra, Canakinumab |
| IL-6 |
Microglia, astrocytes |
Acute phase response |
Tocilizumab |
| IL-18 |
Microglia, macrophages |
IFN-γ induction |
Not tested |
Microglia can adopt distinct activation states:
flowchart LR
A1 ["Pro-inflammatory Stimuli"] --> B1 ["M1 Microglia"]
B["1"]--> C1TNF-α, IL-1β, I["L-12"]
B["1"]--> D1 ["iNOS - NO"]
B["1"]--> E1RO ["S Production"]
A2 ["Anti-inflammatory Stimuli"] --> B2 ["M2 Microglia"]
B["2"]--> C2I ["L-4, IL-10, IL-13"]
B["2"]--> D2 ["Arg1 - Polyamines"]
B["2"]--> E2BDN ["F, IGF-1"]
- Triggered by: IFN-γ, LPS, Aβ, TNF-α
- Markers: CD16, CD32, CD86, iNOS
- Function: Pro-inflammatory, cytotoxic
- Triggered by: IL-4, IL-13, IL-10, glucocorticoids
- Markers: CD206, Arg1, YM1, Fizz1
- Function: Anti-inflammatory, tissue repair
Microglia adopt disease-specific phenotypes:
Stage 1 DAM:
- TREM2-independent
- Downregulation of homeostatic genes
- Upregulation of immune genes
Stage 2 DAM:
- TREM2-dependent
- Phagocytic genes upregulated
- Lipid metabolism genes activated
Neuroinflammation is both a consequence and driver of AD pathology:
- Aβ activates microglia via TLR4 and NLRP3 inflammasome
- IL-1β promotes tau phosphorylation via CDK5 and GSK3β
- TNF-α enhances Aβ production through BACE1 upregulation
- Complement activation (C1q, C3) drives synaptic pruning
- TREM2 variants (R47H, R62H) increase AD risk ~3x
- α-Synuclein aggregates activate microglia via TLR2/TLR4
- NLRP3 inflammasome is activated in PD substantia nigra
- Pro-inflammatory cytokines contribute to dopaminergic neuron death
- Activated microglia surround motor neurons in ALS
- NLRP3 and ASC specks are found in ALS spinal cord
- C9orf72 mutations cause innate immune dysregulation
| Gene |
Variant |
Effect on Neuroinflammation |
Disease |
| TREM2 |
R47H, R62H |
Loss of phagocytic function |
AD |
| CD33 |
rs3865444 |
Increased expression |
AD |
| CR1 |
rs6653641 |
Altered complement |
AD |
| INPP5D |
rs35349669 |
Altered signaling |
AD |
| Target |
Drug Class |
Examples |
Stage |
| TNF-α |
Monoclonal antibodies |
Etanercept |
Phase II |
| IL-1β |
IL-1Ra |
Anakinra |
Phase II |
| NLRP3 |
Inhibitors |
MCC950 |
Preclinical |
| COX-2 |
NSAIDs |
Celecoxib |
Failed |
- TREM2 agonists — enhance phagocytosis
- CD33 blockade — reduce activation
- PPAR-γ agonists — shift phenotype
| Biomarker |
Change in Disease |
| IL-1β |
Increased in AD, PD |
| IL-6 |
Increased in AD |
| TNF-α |
Increased in AD, PD |
| YKL-40 |
Marker of gliosis |
- TSPO PET: Measures microglial activation
¶ Neuroinflammation and Synaptic Dysfunction
Chronic neuroinflammation directly damages synapses:
- Complement-mediated pruning: C1q and C3 tag synapses
- Microglial phagocytosis: Engulfment of synaptic material
- Cytokine toxicity: Direct effects on synaptic proteins
- Oxidative stress: Damage to synaptic membranes
¶ Aging and Neuroinflammation
- Microglial dystrophy: Age-related changes
- Inflammaging: Chronic low-grade inflammation
- Microglial priming: Enhanced inflammatory response
- Reduced clearance: Declining phagocytic capacity
Microglia and astrocytes engage in extensive bidirectional communication that shapes the neuroinflammatory landscape in neurodegenerative diseases. This cross-talk operates through multiple signaling pathways that amplify or suppress inflammatory responses depending on the disease context and stage.
Cytokine-Mediated Communication:
-
IL-1β Signaling: Activated microglia release IL-1β, which potently induces astrocyte reactivity and A1 neurotoxic phenotype formation. IL-1β signaling through IL-1R1 on astrocytes triggers NF-κB activation and production of additional inflammatory mediators, creating feed-forward amplification loops that drive chronic neuroinflammation.
-
TNF-α Signaling: Microglia-derived TNF-α promotes astrocyte production of pro-inflammatory cytokines including IL-6, CCL2, and CXCL10. TNF-α signaling through TNFR1/TNFR2 on astrocytes also contributes to blood-brain barrier disruption and peripheral immune cell recruitment.
-
IL-6 Family Cytokines: Microglia release IL-6 and related cytokines (LIF, CNTF) that activate STAT3 signaling in astrocytes, promoting reactive astrogliosis and modulating the balance between neuroprotective and neurotoxic phenotypes.
Paracrine Factor Signaling:
-
CX3CL1 (Fractalkine): The neuronally-expressed CX3CL1 signals through CX3CR1 on microglia to maintain homeostatic surveillance. Disruption of this signaling axis during neurodegeneration contributes to microglial priming and enhanced inflammatory responses.
-
CCL2 (MCP-1): Astrocyte-derived CCL2 recruits microglia to sites of injury and modulates microglial phagocytic activity. Reciprocally, microglia-derived factors regulate astrocyte CCL2 expression.
-
ATP and Purinergic Signaling: Damage-released ATP activates both microglia and astrocytes through P2X/P2Y receptors. Microglial ATP signaling promotes cytokine release, while astrocyte ATP signaling modulates calcium waves and glutamate homeostasis.
Complement System Crosstalk:
-
C1q Production: Astrocytes and microglia both produce complement component C1q, which tags synapses for elimination. Microglial CR3 receptor mediates engulfment of C1q-opsonized synaptic material.
-
C3 and C3aR Signaling: A1-reactive astrocytes upregulate C3, which signals through C3aR on neurons and microglia to promote synaptic dysfunction and microglial recruitment.
-
TREM2-Complement Interactions: TREM2 signaling modulates microglial response to complement-opsonized targets, linking innate immune recognition to phagocytic clearance.
Alzheimer's Disease:
- Aβ activates both microglia and astrocytes, creating synergistic inflammatory cascades
- Microglial IL-1β drives astrocyte A1 phenotype formation
- TREM2 deficiency impairs microglial clearance of complement-tagged synapses
- Astrocyte-derived complement C1q amplifies microglial synaptic pruning
Parkinson's Disease:
- α-Synuclein activates microglia via TLR2/TLR4, producing inflammatory cytokines
- Astrocytes respond by adopting reactive phenotypes that contribute to dopaminergic neuron vulnerability
- Microglia-astrocyte cross-talk contributes to慢性 neuroinflammation in substantia nigra
Amyotrophic Lateral Sclerosis:
- Astrocyte C3 expression correlates with disease progression
- Microglial complement contributes to motor neuron vulnerability
- Non-cell autonomous toxicity through glia-neuron cross-talk
Targeting microglia-astrocyte cross-talk offers novel therapeutic strategies:
- IL-1β blockade: Anakinra or canakinumab to prevent astrocyte activation
- TREM2 modulation: Agonists to enhance microglial clearance function
- Complement inhibition: C1q or C3 blocking antibodies to reduce synaptic pruning
- Astrocyte phenotype modulation: Promote A2 neuroprotective phenotype
flowchart LR
subgraph Microglia
M1["Activated Microglia"]
M2["DAM Formation"]
M3["Cytokine Release<br/>IL-1β, TNF-α, IL-6"]
end
subgraph Astrocytes
A1["Reactive Astrocytes"]
A2["A1 Neurotoxic"]
A3["A2 Neuroprotective"]
end
M1 -->|"Aβ, α-Syn"| M2
M2 -->|"IL-1β, TNF-α"| A1
M1 -->|"ATP, CCL2"| A1
A1 -->|"C3, CCL2"| M2
A1 -->|"Neurotoxic<br/>Factors"| A2
A3 -->|"Neurotrophic<br/>Factors"| A2
M3 -->|"Feed-forward"| A1
A2 -->|"Synaptic Loss"| M3
Neuroinflammation represents both a consequence of neurodegenerative pathology and an active driver of disease progression. While anti-inflammatory therapies have largely failed, targeting specific pathways (TREM2, NLRP3) shows promise.
Single-cell RNA sequencing has revolutionized our understanding of microglial heterogeneity in neurodegenerative diseases. Disease-associated microglia (DAM) represent a distinct activation state characterized by upregulation of lipid metabolism genes and phagocytic markers. TREM2 plays a critical role in this transition, with loss-of-function variants significantly increasing AD risk.
- CSF1R inhibition: Targeting microglial proliferation and survival through CSF1R blockade offers a novel approach to modulate the microglial compartment
- TREM2 modulation: Agonistic antibodies enhancing phagocytic function
- NLRP3 inhibitors: Direct targeting of inflammasome activation
¶ Neuroinflammatory Cytokines and Receptors Comparison
| Cytokine |
Primary Source |
Receptor |
Signaling |
Pro-inflammatory |
| IL-1β |
Microglia, astrocytes |
IL-1R1/IL-1R2 |
MyD88, NF-κB |
Yes |
| IL-6 |
Microglia, astrocytes |
IL-6R/gp130 |
JAK/STAT |
Context-dependent |
| TNF-α |
Microglia, astrocytes |
TNFR1/TNFR2 |
NF-κB, JNK |
Yes |
| IL-18 |
Microglia |
IL-18R |
MyD88, NF-κB |
Yes |
| IFN-γ |
T cells, NK cells |
IFNGR1/IFNGR2 |
JAK/STAT |
Yes |
| CCL2 |
Astrocytes, microglia |
CCR2 |
Gαi |
Chemoattractant |
| CX3CL1 |
Neurons |
CX3CR1 |
Gαi |
Anti-inflammatory |
| TGF-β |
Astrocytes, microglia |
TβRI/II |
SMAD |
Anti-inflammatory |
| Marker |
M1 (Pro-inflammatory) |
M2 (Anti-inflammatory) |
| CD16/32 |
↑ |
↓ |
| CD86 |
↑ |
↓ |
| CD206 |
↓ |
↑ |
| CD163 |
↓ |
↑ |
| iNOS |
↑ |
↓ |
| Arg1 |
↓ |
↑ |
- NSAIDs: COX-2 inhibitors failed in AD prevention
- Minocycline: Failed in ALS and AD trials
- TNF inhibitors: Limited CNS penetration
- TREM2 modulation: Agonistic antibodies
- CSF1R inhibition: Targeting microglial proliferation
- NLRP3 inhibitors: Direct inflammasome blockade
- Metabolic modulation: Ketogenic diets, NAD+ boosters
- Blood-brain barrier breakdown allows immune cell infiltration
- CD4+ T cells drive autoimmune response
- Microglial activation in demyelinating lesions
- Complement-mediated damage to oligodendrocytes
- Mutant huntingtin activates microglia
- NLRP3 inflammasome in striatal neurons
- Cytokine release contributes to neurodegeneration
- Microglial activation correlates with disease severity
- TREM2 variants affect disease progression
- Neuroinflammation in tau and TDP-43 pathology
The NF-κB pathway is central to neuroinflammation:
- Activation: TLRs, RAGE, TNFR trigger IKK complex
- IκB degradation: Releases p65/p50 dimers
- Nuclear translocation: Binds to κB response elements
- Gene transcription: Pro-inflammatory cytokines, chemokines
Mitogen-activated protein kinases:
- p38 MAPK: Stress-activated, regulates cytokines
- JNK: Jun kinase, apoptosis signaling
- ERK: Growth factor signaling, can be protective
NLRP3 inflammasome formation:
- Priming signal: NF-κB upregulates NLRP3, pro-IL-1β
- Activation signal: ATP, ROS, crystals trigger assembly
- ASC speck formation: Recruitment of ASC adapter
- Caspase-1 activation: Cleaves pro-IL-1β, pro-IL-18
- Pyroptosis: Inflammatory cell death
| Biomarker |
Source |
Disease |
Utility |
| YKL-40 |
Plasma |
AD, MS |
Gliosis marker |
| GFAP |
Plasma |
AD |
Astrocyte activation |
| Neurofilament light |
Plasma |
ALS, AD |
Neuronal damage |
| Tau |
Plasma |
AD |
Neurodegeneration |
- PBR28 PET: TSPO binding in microglia
- PK11195: Alternative TSPO ligand
- FEPET: Monoamine oxidase B imaging
| Gene |
Function |
Effect |
| TREM2 |
Phagocytosis receptor |
Variants increase risk |
| CD33 |
Siglec receptor |
Inhibits phagocytosis |
| CR1 |
Complement receptor |
Affects clearance |
| MS4A4E |
Cell surface protein |
Modulates signaling |
- DNA methylation of inflammatory genes
- Histone modifications in microglia
- Non-coding RNAs as regulators
- CSF cytokines: Support differential diagnosis
- PET imaging: Assess disease activity
- Blood markers: Screening and monitoring
- Timing: Early intervention likely critical
- Combination: Multiple targets may be needed
- Personalization: Genetics may guide therapy
- Single-cell sequencing of microglia
- Spatial transcriptomics of inflammatory pathways
- iPSC models of neuroinflammation
- Organoid systems for drug testing
- Multiplex platforms for cytokine panels
- Ultrasensitive assays for blood detection
- Longitudinal tracking of inflammation
Disease-Associated Microglia (DAM):
- TREM2-dependent activation pathway
- Upregulation of lipid metabolism genes
- Phagocytic phenotype
- Found in AD, ALS, MS
Aging Microglia:
- Senescent phenotype
- Secretory profile changes
- Reduced phagocytosis
- Enhanced inflammatory responses
Activated microglia subtypes:
- CAMs: Conservative activation microglia
- IQRMs: Injury-quickly responding microglia
- ARM: Alternative activation microglia
Astrocytes undergo dramatic changes in disease:
Reactive astrogliosis:
- Proliferation and hypertrophy
- Upregulation of GFAP
- Loss of domain organization
- Gain of neurotoxic functions
A1 vs A2 phenotypes:
- A1: Neurotoxic, induced by IL-1α, TNF, C1q
- A2: Neuroprotective, induced by IL-4, IL-10
- Myelin phagocytosis by microglia
- Precursor cell dysfunction
- Remyelination failure
- Axonal metabolic support loss
¶ Neuroinflammation and Proteinopathies
Aβ drives inflammatory responses:
- Direct activation of TLR4 on microglia
- NLRP3 inflammasome assembly
- Cytokine storm in microenvironment
- Feedback loops amplify pathology
Tau pathology induces inflammation:
- Extracellular tau activates microglia
- Cytokines promote phosphorylation
- Spread via inflammatory mechanisms
- Neuronal loss fuels chronic inflammation
Parkinson's disease features[^21]:
- Aggregates activate microglia
- NLRP3 activation in substantia nigra
- Dopaminergic neuron vulnerability
- Progressive inflammatory cascade
- APP/PS1 mice: Amyloid-driven inflammation
- P301S tau mice: Tauopathy models
- α-synuclein models: PD features
- iPSC-derived microglia
- Patient selection by inflammatory biomarkers
- Endpoint selection beyond cognition
- Imaging correlates for target engagement
- Combination approaches may be needed
- Gene regulatory networks in inflammation
- Protein-protein interactions map pathways
- Metabolic networks in activated glia
- Cross-species comparisons for translation
- Boolean networks of microglial activation
- Ordinary differential equations for signaling
- Agent-based models of cell interactions
- Machine learning for biomarker discovery
- IHC for cytokines and gliosis markers
- RNA in situ hybridization for transcripts
- Electron microscopy of glia
- 3D reconstruction of inflammatory foci
- Bulk RNA-seq of brain tissue
- Single-cell RNA-seq of microglia
- Proteomics of CSF and brain
- Metabolomics of inflammatory states
- Genetic stratification based on inflammatory variants
- Biomarker-driven patient selection
- Targeted therapies for specific mechanisms
- Combination regimens for synergistic effects
- Lifestyle modifications to reduce inflammation
- Early intervention before symptom onset
- Modifiable risk factors targeting
- Longitudinal monitoring of at-risk individuals
- Primary cultures of microglia
- iPSC-derived glia
- Organotypic slice cultures
- Microfluidic devices for migration
- Two-photon microscopy of mouse brain
- ** Longitudinal PET** of inflammation
- Optogenetic control of microglial activity
- Fiber photometry of calcium signals
¶ Circadian Rhythm and Inflammation
Inflammatory responses show daily variation[^23]:
- Clock gene regulation of cytokines
- Melatonin anti-inflammatory effects
- Sleep disruption increases inflammation
- Therapeutic timing considerations
¶ Neuroinflammation and Sleep
- Sleep deprivation activates microglia
- Aβ accumulation during wakefulness
- Glymphatic clearance during sleep
- Bidirectional relationship
- Estrogen anti-inflammatory properties
- Testosterone modulation of microglia
- Menstrual cycle influences
- Postmenopausal vulnerability
- AD prevalence higher in women
- PD progression differs by sex
- Therapeutic response variations
- Personalized approaches needed
- Herpes simplex and AD risk
- Systemic infections impact brain
- Microbiome-gut-brain axis
- Chronic viral infections
- Air pollution activates microglia
- Pesticides and PD risk
- Heavy metals neuroinflammation
- Occupational exposures
- Omega-3 fatty acids reduce inflammation
- Polyphenols antioxidant effects
- Vitamin D immunomodulation
- Caloric restriction benefits
- Obesity increases brain inflammation
- Type 2 diabetes cognitive risk
- Insulin resistance glial dysfunction
- Vascular contributions
- ODE-based cytokine dynamics
- Stochastic activation models
- Network-based inflammation maps
- Patient-specific modeling
- Biomarker prediction from multi-omics
- Image analysis of gliosis
- Drug response modeling
- Patient stratification algorithms
- CSF cytokines as pharmacodynamic markers
- Blood markers for easy monitoring
- Imaging of microglial activation
- Composite endpoints for inflammation
- Cognitive trajectories as primary endpoint
- Functional outcomes secondary measures
- Quality of life assessments
- Biomarker correlations
Neuroinflammation follows predictable patterns[^24]:
- **Hippocam- Substantia nigra: PD-specific vulnerability
- Motor cortex: ALS-specific patterns
- Frontal cortex: FTD features
- Blood-brain barrier limits drug delivery
- Efflux transporters reduce brain concentrations
- Inflammatory barrier changes during disease
- Focused ultrasound for opening BBB
- Multiple pathways involved
- Redundant mechanisms compensate
- Cell-type specificity challenges
- Temporal targeting complexities
- Light-controlled microglial activation
- Circuit-specific manipulation
- Temporal precision in studies
- Translational potential
- DREADDs for microglial modulation
- Designer receptors for specific pathways
- Non-invasive activation possible
- Microglial markers vary between species
- Inflammatory pathways evolutionarily conserved
- Brain structure differences
- Clinical translation failures
- Acute vs chronic inflammation differences
- Genetic background effects
- Environmental factors not replicated
- Therapeutic timing challenges
- Anti-inflammatory gene delivery
- Microglial repopulation strategies
- CRISPR targeting of variants
- Viral vector approaches
- Microglial transplantation
- iPSC-derived glia
- Engineered cells for repair
- Immunomodulatory approaches